Collegium Pharmaceutical, Inc. (COLL) Key Metrics
COLL valuation today
Trailing 12 months · as of October 17, 2026- Market cap
- $755.0M
- Enterprise value
- $1.70B
- P/E (TTM)
- 18.3 10-yr median 26.3
- Forward P/E
- 3.4
- PEG ratio
- —
- Price / sales
- 0.9 10-yr median 2.3
- Price / book
- 2.3 10-yr median 5.2
- EV / EBITDA
- 4.4 10-yr median 5.9
- Dividend yield
- —
- Beta
- 0.73
COLL key metrics, 2016–2025
Fiscal year ended December 31, 2025 · U.S. dollarsCOLL valuation Price multiples at each fiscal year-end price.
COLL returns How much profit the business earns on the capital it uses.
COLL per-share figures Results divided by the shares outstanding at year-end.
COLL financial health Debt, liquidity and how easily interest is covered.
COLL efficiency & capital use Working capital cycle and where the cash goes.
COLL valuation history
COLL returns on capital
Net income (ROE, ROA) or after-tax operating income (ROIC) divided by the average of the opening and closing balance.
COLL debt vs cash
Debt includes short- and long-term borrowings and, where reported, lease liabilities.
COLL cash returned to shareholders
COLL price vs earnings per share
COLL key metrics
2016–2025| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Valuation | ||||||||||
| Market capitalization | $1.84B | $1.16B | $1.29B | $784.8M | $766.7M | $704.1M | $688.5M | $565.8M | $558.7M | $377.8M |
| Enterprise value | $2.37B | $1.85B | $1.65B | $1.32B | $839.1M | $796.5M | $540.1M | $430.7M | $441.5M | $228.7M |
| P/E ratio | 29.2 | 16.7 | 26.7 | — | 10.7 | 26.3 | — | — | — | — |
| Price / sales | 2.4 | 1.8 | 2.3 | 1.7 | 2.8 | 2.3 | 2.3 | 2.0 | 19.6 | 220.8 |
| Price / book | 6.1 | 5.1 | 6.6 | 4.0 | 3.8 | 3.8 | 7.9 | 6.2 | 5.4 | 2.8 |
| Price / free cash flow | 5.6 | 5.7 | 4.7 | 6.4 | 7.5 | — | 32.3 | 3.9 | — | — |
| Price / operating cash flow | 5.6 | 5.7 | 4.7 | 6.3 | 7.4 | 7.5 | 24.8 | 3.3 | — | — |
| EV / sales | 3.0 | 2.9 | 2.9 | 2.8 | 3.0 | 2.6 | 1.8 | 1.5 | 15.5 | 133.7 |
| EV / EBITDA | 5.9 | 5.4 | 5.4 | 7.6 | 9.7 | 6.7 | — | 4.7 | — | — |
| EV / free cash flow | 7.2 | 9.1 | 6.0 | 10.8 | 8.3 | — | 25.3 | 3.0 | — | — |
| Earnings yield | 3.4% | 6.0% | 3.7% | −3.2% | 9.3% | 3.8% | −3.3% | −6.9% | −13.4% | −24.9% |
| Free cash flow yield | 17.8% | 17.6% | 21.3% | 15.6% | 13.3% | −39.7% | 3.1% | 25.6% | −12.2% | −20.7% |
| Dividend yield | — | — | 0.7% | — | 1.7% | 1.0% | — | — | 0.1% | 6.5% |
| Shareholder yield (dividends + buybacks) | 1.4% | 5.2% | 6.5% | 1.8% | 7.9% | 1.4% | 0.1% | 0.1% | 0.1% | 6.5% |
| Share price at fiscal year-end | $46.30 | $28.65 | $30.78 | $23.20 | $18.68 | $20.03 | $20.58 | $17.17 | $18.46 | $15.57 |
| Per share | ||||||||||
| Revenue per share | $19.66 | $15.62 | $13.56 | $13.71 | $6.75 | $8.82 | $8.87 | $8.51 | $0.94 | $0.07 |
| Earnings per share | $1.58 | $1.71 | $1.15 | −$0.74 | $1.74 | $0.76 | −$0.68 | −$1.19 | −$2.47 | −$3.88 |
| Operating cash flow per share | $8.29 | $5.07 | $6.57 | $3.67 | $2.52 | $2.67 | $0.83 | $5.14 | −$2.21 | −$3.09 |
| Free cash flow per share | $8.25 | $5.03 | $6.56 | $3.62 | $2.48 | −$7.96 | $0.64 | $4.40 | −$2.25 | −$3.22 |
| Cash per share | $10.24 | $4.03 | $7.43 | $5.13 | $4.54 | $4.95 | $5.08 | $4.45 | $3.92 | $6.32 |
| Book value per share | $7.60 | $5.66 | $4.68 | $5.76 | $4.94 | $5.29 | $2.61 | $2.78 | $3.44 | $5.56 |
| Tangible book value per share | −$12.94 | −$20.41 | −$8.62 | −$14.97 | −$1.60 | −$4.26 | $1.73 | $1.44 | $3.44 | $5.47 |
| Dividends per share | — | — | $0.22 | — | $0.31 | $0.21 | — | — | $0.02 | $1.01 |
| Capex per share | $0.04 | $0.04 | $0.01 | $0.05 | $0.05 | $10.63 | $0.19 | $0.74 | $0.03 | $0.12 |
| Debt per share | $23.69 | $21.26 | $16.14 | $20.96 | $6.30 | $7.58 | $0.65 | $0.35 | $0.05 | $0.17 |
| Shares outstanding | 39.7M | 40.4M | 41.8M | 33.8M | 41.0M | 35.2M | 33.5M | 33.0M | 30.3M | 24.3M |
| Change in shares outstanding | −1.8% | −3.3% | +23.5% | −17.6% | +16.8% | +5.1% | +1.5% | +8.9% | +24.7% | +79.2% |
| Returns & profitability | ||||||||||
| Return on equity (ROE) | 23.7% | 32.6% | 24.7% | −12.6% | 36.8% | 19.6% | −25.4% | −40.0% | −62.7% | −85.6% |
| Return on invested capital (ROIC) | 14.4% | 16.1% | 16.5% | 5.2% | 5.0% | 50.2% | — | — | — | — |
| Return on assets (ROA) | 3.8% | 4.9% | 4.2% | −2.7% | 10.7% | 5.6% | −7.6% | −18.3% | −50.3% | −72.5% |
| Return on tangible assets | 7.5% | 11.3% | 8.2% | −5.3% | 16.9% | 8.7% | −8.2% | −15.8% | −55.2% | −58.9% |
| Free cash flow margin | 42.0% | 32.2% | 48.4% | 26.4% | 36.7% | −90.3% | 7.2% | 51.7% | −238.8% | — |
| Income quality (OCF / net income) | 5.24 | 2.96 | 5.71 | — | 1.45 | 3.51 | — | — | — | — |
| Financial health | ||||||||||
| Total debt | $940.6M | $859.3M | $674.3M | $709.2M | $258.8M | $266.6M | $21.6M | $11.5M | $1.5M | $4.2M |
| Cash & short-term investments | $406.5M | $162.8M | $310.5M | $173.7M | $186.4M | $174.1M | $170.0M | $146.6M | $118.7M | $153.2M |
| Net debt | $534.0M | $696.5M | $363.7M | $535.5M | $72.3M | $92.5M | −$148.4M | −$135.1M | −$117.2M | −$149.0M |
| Debt / equity | 3.12 | 3.75 | 3.45 | 3.64 | 1.28 | 1.43 | 0.25 | 0.13 | 0.01 | 0.03 |
| Debt / assets | 0.57 | 0.52 | 0.59 | 0.60 | 0.37 | 0.41 | 0.07 | 0.04 | 0.01 | 0.03 |
| Net debt / EBITDA | 1.33 | 2.04 | 1.18 | 3.09 | 0.84 | 0.78 | — | −1.47 | — | — |
| Current ratio | 1.57 | 0.95 | 1.17 | 0.97 | 1.13 | 1.16 | 1.27 | 1.27 | 4.24 | 6.92 |
| Quick ratio | 1.48 | 0.88 | 1.10 | 0.86 | 1.07 | 1.10 | 1.22 | 1.23 | 4.18 | 6.86 |
| Interest coverage | 2.3 | 2.3 | 2.0 | 0.5 | 0.8 | 1.9 | -26.1 | -1.0 | -129.6 | — |
| Working capital | $251.4M | −$27.3M | $79.7M | −$13.7M | $36.0M | $38.4M | $54.0M | $50.0M | $102.0M | $135.6M |
| Invested capital | $835.7M | $925.4M | $559.2M | $730.3M | $275.3M | $278.5M | −$61.0M | −$43.5M | −$13.1M | −$14.1M |
| Tangible asset value | −$513.8M | −$824.9M | −$360.1M | −$506.3M | −$65.8M | −$149.9M | $57.9M | $47.3M | $104.1M | $132.8M |
| Net current asset value | −$663.7M | −$952.5M | −$410.3M | −$559.3M | −$173.6M | −$179.9M | $36.9M | $37.9M | $102.0M | $131.5M |
| Graham number | $16.45 | $14.77 | $11.01 | — | $13.92 | $9.52 | — | — | — | — |
| Graham net-net per share | −$19.39 | −$26.79 | −$11.64 | −$19.07 | −$5.23 | −$6.07 | $0.32 | $0.28 | $3.16 | $5.29 |
| Capital allocation | ||||||||||
| Dividends paid | — | — | $9.1M | — | $12.7M | $7.3M | — | — | $736,000 | $24.6M |
| Share buybacks (net) | $25.1M | $60.0M | $75.0M | $14.1M | $47.9M | $2.3M | $822,000 | $560,000 | $0 | $0 |
| Dividend payout ratio | — | — | 18.9% | — | 17.8% | 27.4% | — | — | — | — |
| Dividends + buybacks / free cash flow | 7.7% | 29.5% | 30.7% | 11.5% | 59.6% | — | 3.9% | 0.4% | — | — |
| Capex / revenue | 0.2% | 0.3% | 0.1% | 0.3% | 0.7% | 120.6% | 2.2% | 8.7% | 3.5% | 174.0% |
| Capex / operating cash flow | 0.5% | 0.8% | 0.2% | 1.3% | 1.9% | 397.9% | 23.2% | 14.4% | — | — |
| Capex / depreciation | 0.01 | 0.01 | 0.00 | 0.01 | 0.03 | 6.07 | 0.42 | 0.22 | 1.67 | 4.55 |
| Stock-based compensation / revenue | 5.4% | 5.1% | 4.8% | 4.9% | 8.8% | 7.1% | 5.6% | 4.9% | 27.9% | 338.2% |
| R&D / revenue | — | — | — | 0.9% | 3.4% | 3.2% | 3.5% | 3.1% | 30.1% | 873.6% |
| SG&A / revenue | 36.5% | 29.0% | 28.1% | 37.1% | 43.0% | 36.7% | 39.2% | 45.2% | 325.7% | 4,712.6% |
| Efficiency | ||||||||||
| Days sales outstanding | 102.8 | 117.9 | 116.8 | 113.7 | 124.7 | 92.0 | 92.8 | 57.2 | 77.5 | 454.2 |
| Days of inventory on hand | 44.0 | 48.8 | 59.8 | 45.8 | 47.7 | 35.4 | 16.5 | 10.6 | 220.1 | 1,127.6 |
| Days payables outstanding | 8.4 | 9.1 | 9.2 | 5.5 | 20.5 | 22.8 | 17.3 | 19.6 | 1,664.6 | 20,349.2 |
| Cash conversion cycle (days) | 138.4 | 157.6 | 167.3 | 154.0 | 151.9 | 104.6 | 91.9 | 48.2 | -1,367.0 | -18,767.4 |
| Receivables turnover | 3.55 | 3.09 | 3.13 | 3.21 | 2.93 | 3.97 | 3.93 | 6.38 | 4.71 | 0.80 |
| Payables turnover | 43.49 | 40.25 | 39.49 | 66.24 | 17.78 | 16.01 | 21.05 | 18.58 | 0.22 | 0.02 |
| Inventory turnover | 8.30 | 7.49 | 6.10 | 7.96 | 7.65 | 10.31 | 22.18 | 34.41 | 1.66 | 0.32 |
| Asset turnover | 0.47 | 0.45 | 0.49 | 0.50 | 0.41 | 0.65 | 0.99 | 1.31 | 0.19 | 0.01 |
| Average receivables | $219.9M | $204.0M | $181.3M | $144.5M | $94.6M | $78.1M | $75.4M | $44.0M | $6.0M | $2.1M |
| Average payables | $7.3M | $6.3M | $6.1M | $3.8M | $7.1M | $8.1M | $9.2M | $8.9M | $11.8M | $11.9M |
| Average inventory | $38.2M | $33.9M | $39.4M | $31.9M | $16.5M | $12.6M | $8.7M | $4.8M | $1.6M | $658,000 |
| Intangibles / total assets | 49.2% | 63.3% | 48.6% | 59.7% | 38.8% | 52.2% | 9.6% | 15.2% | 0.0% | 1.3% |
Computed from COLL's annual financial statements (latest annual report filed February 26, 2026) and the closing share price on each fiscal year-end, adjusted for stock splits. Figures in U.S. dollars; data from EODHD. Averages use the opening and closing balance of each year.
COLL valuation and financial ratios
At the end of fiscal 2025 (December 31, 2025), Collegium Pharmaceutical traded at 29.2 times earnings, against a 10-year median of 26.3. Based on the latest twelve months, the trailing P/E is 18.3 and the forward P/E is 3.4. Collegium Pharmaceutical earned a return on equity of 23.7% and a return on invested capital of 14.4% in fiscal 2025. It ended the year with $940.6 million of debt and $406.5 million in cash and short-term investments, net debt of $534.0 million. It returned $25.1 million to shareholders: $0 in dividends and $25.1 million in share buybacks, 8% of free cash flow. The share count rose 63.6% from 24.3M to 39.7M over 9 years.
See the COLL income statement, the COLL chart for price history, or the COLL stock overview for the latest quote and news.
COLL key metrics FAQ
What is Collegium Pharmaceutical's P/E ratio?
Collegium Pharmaceutical's trailing P/E ratio is 18.3 based on the last twelve months of earnings (as of October 17, 2026), and its forward P/E is 3.4. At the end of fiscal 2025 it was 29.2, compared with a 10-year median of 26.3.
What is Collegium Pharmaceutical's EV/EBITDA?
Collegium Pharmaceutical's enterprise value was 5.9 times EBITDA at the end of fiscal 2025 (enterprise value $2.4 billion, EBITDA $401.0 million); the current EV/EBITDA is 4.4.
What is Collegium Pharmaceutical's return on equity?
Collegium Pharmaceutical's return on equity (ROE) was 23.7% in fiscal 2025: net income of $62.9 million on average shareholders' equity of $265.3 million.
What is Collegium Pharmaceutical's ROIC?
Collegium Pharmaceutical's return on invested capital was 14.4% in fiscal 2025, using after-tax operating income divided by average debt plus equity minus cash.
How much debt does Collegium Pharmaceutical have?
Collegium Pharmaceutical had total debt of $940.6 million at the end of fiscal 2025, a debt-to-equity ratio of 3.12 and $534.0 million of net debt (1.33 times EBITDA).
Does Collegium Pharmaceutical buy back its shares?
Yes. Collegium Pharmaceutical spent $25.1 million on net share repurchases in fiscal 2025 Shares outstanding changed −1.8% over the year, to 39.7M..
What is Collegium Pharmaceutical's free cash flow yield?
Collegium Pharmaceutical generated $327.6 million of free cash flow in fiscal 2025, a free cash flow yield of 17.8% on its market value at year-end ($1.8 billion).
What is Collegium Pharmaceutical's current ratio?
Collegium Pharmaceutical's current ratio was 1.57 at the end of fiscal 2025: current assets were 1.57 times current liabilities.